Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R0.6C vaccine
- Development stage
- Phase 1
- Lead developer
- Radboud University Medical Center
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
R0.6C is a transmission-blocking malaria vaccine candidate developed by Radboud University Medical Center. It is a recombinant fusion protein consisting of the Pfs48/45 domain 3 (designated 6C) and the N-terminal region of the Plasmodium falciparum glutamate-rich protein (GLURP, designated R0). The vaccine is produced using a *Lactococcus lactis* expression system. Its mechanism of action involves inducing antibodies in the human host that, when ingested by a mosquito during a blood meal, target the Pfs48/45 protein on the surface of the parasite's sexual stages. This interaction blocks the development of the parasite within the mosquito gut, thereby preventing the transmission of malaria to other humans. The vaccine has been evaluated in Phase I clinical trials (STOP-TRANS study) using either Alhydrogel (aluminum hydroxide) or Matrix-M1 as adjuvants.
- Other names
- R0.6C malaria vaccineR-0.6C malaria vaccineR 0.6C malaria vaccineR0.6C transmission-blocking vaccineR-0.6C transmission-blocking vaccineR 0.6C transmission-blocking vaccine
02
Targets
GLURP (Plasmodium falciparum glutamate-rich protein)Pfs48/45
Beyond the preview
Go deeper on R0.6C vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R0.6C vaccine.